Birchview Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Birchview Capital’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,592	Closed	-$55K	–	46
2017 Q2	$55K	Hold	5,592	–	–	0.03%	41
2017 Q1	$136K	Hold	5,592	–	–	0.08%	40
2016 Q4	$180K	Hold	5,592	–	–	0.11%	37
2016 Q3	$279K	Hold	5,592	–	–	0.16%	30
2016 Q2	$237K	Hold	5,592	–	–	0.17%	30
2016 Q1	$368K	Buy	5,592 +1,779	+47%	+$92.9K	0.26%	26
2015 Q4	$237K	Sell	3,813 -1,563	-29%	-$110K	0.14%	35
2015 Q3	$360K	Hold	5,376	–	–	0.23%	31
2015 Q2	$523K	Hold	5,376	–	–	0.28%	26
2015 Q1	$503K	Hold	5,376	–	–	0.26%	28
2014 Q4	$478K	Buy	+5,376	New	+$392K	0.28%	25

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Birchview Capital's MACK Position: Q3 2017 in Review

Birchview Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 5,592 shares — an estimated $55K sold.

Birchview Capital first reported a position in MACK in Q4 2014 and held it in 11 quarters. The position peaked at $523K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Birchview Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Birchview Capital sold 5,592 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $55K.
Birchview Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
Birchview Capital's Merrimack Pharmaceuticals, Inc. position peaked at $523K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Birchview Capital's 13F filing for Q3 2017, filed 2 Nov 2017.